Joey Azofeifa was trained as a computational geneticist at the University of Colorado - Boulder. He has published extensively at the intersection of machine learning, mathematics and genomics. Specifically, his work pioneered the use of enhancer RNAs to identify the mechanism of action of early drug candidates. Following training, Joey has worked as a computational biologist at pharmaceutical companies such as Merck and Forma Therapeutics. Joey recently started Arpeggio Bio, a preclinical stage drug discovery that is leveraging a new type of RNA sequencing to find targets for hard to treat cancers.